早期规律使用润肤剂在新生儿特应性皮炎防治中作用

doi:10.12372/jcp.2024.23e1132

摘要/Abstract

摘要：

皮肤屏障功能受损在特应性皮炎（atopic dermatitis，AD）的发生中起重要作用。润肤剂可以通过增强皮肤屏障功能，减少经皮水分丢失，维持角质层的水合状态。特应性皮炎与食物过敏、过敏性鼻炎、过敏性哮喘有密切关系。早期有效预防AD发生的措施可以减少家庭及社会的经济负担。本文就AD与皮肤屏障及过敏性疾病之间的关系，以及润肤剂在预防AD的应用中进行综述，讨论新生儿早期规律使用润肤剂能否有效预防特应性皮炎的发生以及降低过敏性疾病的风险。

关键词: 特应性皮炎, 润肤剂, 皮肤屏障, 过敏性疾病

Abstract:

Impaired epidermal barrier function plays a pivotal role in the pathogenesis of atopic dermatitis (AD). Emollients can fortify the skin barrier, diminish transepidermal water loss, and maintain stratum corneum hydration. AD is closely associated with comorbidities such as food allergies, allergic rhinitis, and allergic asthma. Implementing effective preventive measures in the early stages of AD can alleviate the economic burden on families and society. This review explores the relationship between AD and skin barrier and allergic diseases, as well as the application of emollients in the prevention of AD, and discusses whether regular use of emollients in early neonates can effectively prevent the occurrence of atopic dermatitis and reduce the risk of allergic diseases.

Key words: atopic dermatitis, emollient, epidermal barrier, allergic disease

唐钏乂, 姚志荣. 早期规律使用润肤剂在新生儿特应性皮炎防治中作用[J]. 临床儿科杂志, 2024, 42(9): 817-821.

TANG Chuanyi, YAO Zhirong. The role of early regular use of emollients in the prevention and treatment of infantile atopic dermatitis[J]. Journal of Clinical Pediatrics, 2024, 42(9): 817-821.

参考文献 48

[1]	中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南(2020版)[J]. 中华皮肤科杂志, 2020, 53(2): 81-88.
[2]	顾恒, 尤立平, 刘永生, 等. 我国10城市学龄前儿童特应性皮炎现况调查[J]. 中华皮肤科杂志, 2004, 37(1): 29-31.
[3]	Guo Y, Li P, Tang J, et al. Prevalence of atopic dermatitis in Chinese children aged 1-7ys[J]. Sci Rep, 2016, 6: 29751.
[4]	Guo Y, Zhang H, Liu Q, et al. Phenotypic analysis of atopic dermatitis in children aged 1-12 months: elaboration of novel diagnostic criteria for infants in China and estimation of prevalence[J]. J Eur Acad Dermatol Venereol. 2019, 33(8): 1569-1576. doi: 10.1111/jdv.15618 pmid: 30989708
[5]	Gonzalez-U, Vidaurri C, Gomez-Nuñez A, et al. Comorbidities & burden of disease in atopic dermatitis[J]. Asian Pac J Allergy Immunol, 2023, 41(2): 97-105.
[6]	Domínguez O, Plaza AM, Alvaro M. Relationship between atopic dermatitis and food allergy[J]. Curr Pediatr Rev, 2020, 16(2): 115-122. doi: 10.2174/1573396315666191111122436 pmid: 31713486
[7]	Yang L, Fu J, Zhou Y. Research progress in atopic march[J]. Front Immunol, 2020, 11: 1907. doi: 10.3389/fimmu.2020.01907 pmid: 32973790
[8]	Luger T, Amagai M, Dreno B, et al. Atopic dermatitis: role of the skin barrier, environment, microbiome, and therapeutic agents[J]. J Dermatol Sci, 2021, 102(3): 142-157. doi: 10.1016/j.jdermsci.2021.04.007 pmid: 34116898
[9]	Kim Y, Lim KM. Skin barrier dysfunction and filaggrin[J]. Arch Pharm Res, 2021, 44(1): 36-48. doi: 10.1007/s12272-021-01305-x pmid: 33462753
[10]	Bataille V, Lens M, Spector TD. The use of the twin model to investigate the genetics and epigenetics of skin diseases with genomic, transcriptomic and methylation data[J]. J Eur Acad Dermatol Venereol, 2012, 26(9): 1067-1073. doi: 10.1111/j.1468-3083.2011.04444.x pmid: 22243446
[11]	Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms[J]. Allergy Clin Immunol, 2008, 121(6): 1337-1343.
[12]	Moosbrugger V, Leprince C, Méchin MC, et al. Revisiting the roles of filaggrin in atopic dermatitis[J]. Int J Mol Sci, 2022, 23(10): 5318.
[13]	Yang G, Seok JK, Kang HC, et al. Skin barrier abnormalities and immune dysfunction in atopic dermatitis[J]. Int J Mol Sci, 2020, 21(8): 2867.
[14]	Edslev SM, Agner T, Andersen PS. Skin microbiome in atopic dermatitis[J]. Acta Derm Venereol, 2020, 100(12): adv00164.
[15]	Baker P, Huang C, Radi R, et al. Skin barrier function: the interplay of physical, chemical, and immunologic properties[J]. Cells, 2023, 12(23): 2745.
[16]	Tsuge M, Ikeda M, Matsumoto N, et al. Current insights into atopic march[J]. Children (Basel), 2021, 8(11): 1067.
[17]	Lack G. Epidemiologic risks for food allergy[J]. J Allergy Clin Immunol, 2008, 121(6): 1331-1336. doi: 10.1016/j.jaci.2008.04.032 pmid: 18539191
[18]	Dębińska A, Sozańska B. Epicutaneous sensitization and food allergy: preventive strategies targeting skin barrier repair-facts and challenges[J]. Nutrients, 2023, 15(5): 1070.
[19]	Allenova A, Darlenski R. The hen and the egg question in atopic dermatitis: allergy or eczema comes first[J]. Asthma Res Pract, 2023, 9(1): 1.
[20]	Ramírez-Marín HA, Singh AM, Ong PY, et al. Food allergy testing in atopic dermatitis[J]. JAAD Int, 2022, 9: 50-56.
[21]	Giannetti A, Cipriani F, Indio V, et al. Influence of atopic dermatitis on cow's milk allergy in children[J]. Medicina (Kaunas), 2019, 55(8): 460.
[22]	Yang L, Fu J, Zhou Y. Research progress in atopic march[J]. Front Immunol, 2020, 11: 1907. doi: 10.3389/fimmu.2020.01907 pmid: 32973790
[23]	Langan S, Irvine A, Weidinger S. Atopic dermatitis[J]. Lancet, 2020, 396(10247): 345-360. doi: S0140-6736(20)31286-1 pmid: 32738956
[24]	Yuhouvon Kobyletzki LB, Bornehag CG, Hasselgren M, et al. Eczema in early childhood is strongly associated with thedevelopment of asthma and rhinitis in a prospective cohort[J]. BMC Dermatol, 2012, 12: 11. doi: 10.1186/1471-5945-12-11 pmid: 22839963
[25]	Matsumoto K, Iikura K, Morita H, et al. Barrier dysfunction in the atopic march-how does atopic dermatitis lead to asthma in children?[J]. J Allergy Clin Immunol, 2020, 145(6): 1551-1553. doi: S0091-6749(20)30558-3 pmid: 32344057
[26]	Umar BU, Rahman S, Dutta S, et al. Management of atopic dermatitis: the role of Tacrolimus[J]. Cureus, 2022, 14(8): e28130.
[27]	Fu H, Li Y, Huang H, et al. Serum vitamin D level and efficacy of vitamin D supplementation in children with atopic dermatitis: a systematic review and meta-analysis[J]. Comput Math Methods Med, 2022, 2022: 9407888.
[28]	Miyaji Y, Yang L, Yamamoto-Hanada K, et al. Earlier aggressive treatment to shorten the duration of eczema in infants resulted in fewer food allergies at 2 years of age[J]. J Allergy Clin Immunol Pract, 2020, 8(5):1721-1724. doi: S2213-2198(19)31018-9 pmid: 31821918
[29]	Uwe, Matterne, Merle, et al. Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema[J]. Cochrane Database Syst Rev, 2019, 1(1): CD012167.
[30]	Miyaji Y, Yang L, Yamamoto-Hanada K, et al. Earlier aggressive treatment to shorten the duration of eczema in infants resulted in fewer food allergies at 2 years of age[J]. J Allergy Clin Immunol Pract, 2020, 8(5): 1721-1724. doi: S2213-2198(19)31018-9 pmid: 31821918
[31]	Uwe, Matterne, Merle, et al. Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema[J]. Cochrane Database Syst Rev, 2019, 1(1): CD012167.
[32]	Williams HC, Chalmers J. Prevention of atopic dermatitis[J]. Acta Derm Venereol, 2020, 100(12): adv00166.
[33]	Rajkumar J, Chandan N, Lio P, et al. The skin barrier and moisturization: function, disruption, and mechanisms of repair[J]. Skin Pharmacol Physiol, 2023, 36(4): 174-185.
[34]	Gupta J, Grube E, Ericksen MB, et al. Intrinsically defective skin barrier function in children with atopic dermatitis correlates with disease severity[J]. J Allergy Clin Immunol, 2008, 121(3): 725-730. doi: 10.1016/j.jaci.2007.12.1161 pmid: 18249438
[35]	Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies[J]. J Am Acad Dermatol, 2023, 89(1): e1-e20. doi: 10.1016/j.jaad.2022.12.029 pmid: 36641009
[36]	Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations[J]. J Eur Acad Dermatol Venereol, 2022, 36(11): 1904-1926. doi: 10.1111/jdv.18429 pmid: 36056736
[37]	Saeki H, Ohya Y, Furuta J, et al. English version of clinical practice guidelines for the management of atopic dermatitis 2021[J]. J Dermatol, 2022, 49(10):e315-e375.
[38]	Gupta S, Ramam M, Sharma VK, et al. Evaluation of a paraffin-based moisturizer compared to a ceramide-based moisturizer in children with atopic dermatitis: a double-blind, randomized controlled trial[J]. Pediatr Dermatol, 2023, 40(4):627-632. doi: 10.1111/pde.15355 pmid: 37269189
[39]	Piquero-Casals J, Morgado-Carrasco D, Granger C, et al. Urea in dermatology: a review of its emollient, moisturizing, keratolytic, skin barrier enhancing and antimicrobial properties[J]. Dermatol Ther (Heidelb), 2021, 11(6): 1905-1915.
[40]	Dębińska A. New treatments for atopic dermatitis targeting skin barrier repair via the regulation of FLG expression[J]. J Clin Med, 2021, 10(11): 2506.
[41]	Danby SG, Andrew PV, Taylor RN, et al. Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitis[J]. Clin Exp Dermatol, 2022, 47(6): 1154-1164. doi: 10.1111/ced.15141 pmid: 35167133
[42]	Lun HK, Charmaine KJS, Gigi NWG, et al. Emollient treatment of atopic dermatitis: latest evidence and clinical considerations[J]. Drugs Context, 2018, 7: 212530.
[43]	Lowe A, Su J, Allen K, et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study[J]. Br J Dermatol, 2018, 178(1): e19-e21.
[44]	Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention[J]. J Allergy Clin Immunol, 2014, 34(4): 818-823.
[45]	Horimukai K, Morita K, Narita M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis[J]. J Allergy Clin Immunol, 2014, 134(4): 824-830. doi: 10.1016/j.jaci.2014.07.060 pmid: 25282564
[46]	Lowe A, Su J, Tang M, et al. PEBBLES study protocol: a randomised controlled trial to prevent atopic dermatitis, food allergy and sensitisation in infants with a family history of allergic disease using a skin barrier improvement strategy[J]. BMJ Open, 2019, 9(3): e024594.
[47]	Skjerven HO, Rehbinder EM, Vettukattil R, et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial[J]. Lancet, 2020, 395(10228): 951-961. doi: S0140-6736(19)32983-6 pmid: 32087121
[48]	Chalmers JR, Haines RH, Bradshaw LE, et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial[J]. Lancet, 2020, 395(10228): 962-972. doi: S0140-6736(19)32984-8 pmid: 32087126